<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109295">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950364</url>
  </required_header>
  <id_info>
    <org_study_id>C25005</org_study_id>
    <secondary_id>2013-000193-29</secondary_id>
    <nct_id>NCT01950364</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma</brief_title>
  <official_title>A Phase 1 Study to Estimate MMAE Metabolites in Human Plasma and Urine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Receiving Brentuximab Vedotin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>European Union: European Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label trial to estimate the concentrations of MMAE in relapsed/refractory HL
      or relapsed/refractory sALCL patients treated with either brentuximab vedotin or brentuximab
      vedotin + rifampicin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma and urine concentrations of MMAE and its major metabolites</measure>
    <time_frame>Various timepoints during  Day 1 of Cycles 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ADC and TAb (free and ADC-bound)</measure>
    <time_frame>Various timepoints during Day 1 of Cycles 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence of ATA to brentuximab vedotin</measure>
    <time_frame>Day 1 of Cycles 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs, serious adverse events (SAEs), assessments of clinical laboratory values, and vital sign measurements</measure>
    <time_frame>From signing informed consent through 30 days after the last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Anaplastic Large-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Brentuximab vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Brentuximab vedotin and rifampicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.</description>
    <arm_group_label>Arm A: Brentuximab vedotin</arm_group_label>
    <other_name>SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab vedotin and rifampicin</intervention_name>
    <description>Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.</description>
    <arm_group_label>Arm B: Brentuximab vedotin and rifampicin</arm_group_label>
    <other_name>SGN-35</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between 18 years and 75 years old, with relapsed or
             refractory HL or relapsed or refractory sALCL who have previously received at least 1
             multiagent chemotherapy

          -  Measurable disease

          -  An Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1

          -  Female patients who are postmenopausal for at least 1 year before the screening
             visit, surgically sterile, or agree to practice 2 effective methods of contraception,
             at the same time, from the time of signing the informed consent form through 30 days
             after the last dose of study drug, or agree to practice true abstinence

          -  Male patients who agree to practice effective barrier contraception during the entire
             study treatment period through 6 months after the last dose of study drug or agree to
             practice true abstinence

          -  Clinical laboratory values as specified in the study protocol

        Exclusion Criteria:

          -  Patients for whom rifampicin is contraindicated

          -  Previously received an allogeneic transplant.

          -  Patients with current diagnosis of primary cutaneous ALCL (patients whose ALCL has
             transformed to sALCL are eligible).

          -  Known cerebral/meningeal disease including signs or symptoms of progressive
             multifocal leukoencephalopathy (PML)

          -  Female patients who are lactating and breastfeeding or pregnant

          -  Known human immunodeficiency virus (HIV) positive,

          -  Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C
             infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For an updated listing of recruitment sites contact: Millennium  Medical and Drug Information Center</last_name>
    <phone>1-877-674-3784</phone>
    <email>medical@mlnm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Hodgkin</keyword>
  <keyword>Anaplastic Large-cell</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Antigens, CD30</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Lymphoma, Large-Cell, Anaplastic</keyword>
  <keyword>Monomethyl auristatin E</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Hematologic Diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
